Patricia Weiser, Pharm.D.

Cancer patients not only experience the physical and mental toll of treatments like chemotherapy but also face "financial toxicity" due to high out-of-pocket costs, which can challenge their ability to work.

Crenolanib may have advantages over other therapies targeting acute myeloid leukemia with FLT3 gene mutations.

Darzalex (daratumumab) is a monoclonal antibody drug currently approved for both refractory and new multiple myeloma. It’s available in intravenous and subcutaneous formulations.

This decision may lead to faster approval of new treatments for multiple myeloma.

A group of researchers recently aimed to investigate the prognosis of patients with NSCLC that lacked a spouse, family members, or friends to support them during cancer treatment.

The term "time toxicity" has been coined for the large amounts of time taken up healthcare that may interfere with other priorities.

A recent study published in NEJM Evidence suggests that minority patients may not have equal access to CAR T-cell therapies, despite the potential life-saving benefits they offer.

Enhertu demonstrated antitumor activity against HER2-overexpressing metastatic NSCLC in the trial.

Last week, BMS announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has voted in favor of BMS’s and 2seventy bio's Abecma (idecabtagene vicleucel) for patients with relapsed or refractory multiple myeloma in earlier lines of therapy.

The trial evaluated Adcetris in combination with Revlimid and Rituxan compared to Revlimid and Rituxan plus placebo in adult patients with relapsed/refractory DLBCL who have received two or more prior lines of therapy and are ineligible for stem cell transplant or CAR-T therapy.

Small cell lung cancer is a less common form of lung cancer and very aggressive. Researchers and drug developers are looking for new treatments, especially for patients whose cancers have stopped responding to first- and second-line treatments. Tarlatamab, a bispecific T-cell engager, looks promising as a third-line treatment.

In the U.S., nearly 200,000 new cases of lung cancer were reported in 2020, with over 100,000 deaths. While the number of lung cancer deaths has generally decreased over the past 20 years, lung cancer remains the leading cause of cancer deaths in the US and is the third most common type of cancer.

Mutations in the FLT3 gene are common in AML, occurring in around 30% of cases, and tend to be associated with poorer outcomes.

A study found that the mRNA-1647 vaccine candidate developed by Moderna elicited strong immune responses. The mRNA vaccine is now in phase 3 clinical trials to determine its effectiveness in protecting against CMV.

Initial treatments for lung adenocarcinomas may be effective at first, but sometimes these tumors can respond by turning into small cell lung cancer (SCLC), a more aggressive and difficult-to-treat disease.

Imbruvica is an oral medication prescribed to treat certain B-cell malignancies, including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and Waldenstrom macroglobulinemia.

The development of new and improved therapeutic agents has improved the treatment outcomes for MM over the past few decades. It remains unclear whether these racial disparities have persisted in the era of novel agents.

It is well-known that smoking is linked to a higher risk of cancer, and those who smoke can lower their risk by quitting. However, it remains unclear exactly how many years of continued smoking cessation are needed to see a substantial risk reduction.

A study published in The Lancet revealed the efficacy of a single-dose typhoid conjugate vaccine. The four-year, phase 3 trial assessed the vaccine's effectiveness in preventing typhoid fever in Malawian children.

The FDA orders new warnings for CAR-T cell therapies due to reports of T-cell malignancies, including fatal cases, applying to BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies.

The FDA orders new warnings for CAR-T cell therapies due to reports of T-cell malignancies, including fatal cases, applying to BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies.

Invivyd‘s request for EUA is supported by positive initial results from the CANOPY Phase 3 clinical trial of VYD222.